How a lack of analogues could have undervalued a promising in-licensing opportunity

High unmet need offered a promising environment for a new asset; however, with no obvious analogues to quantify price potential, an approach ideal for an indication with no current treatments was needed…

Back to Case Studies

A great opportunity for a new asset, in an indication with no current therapies...

A top 20 pharma company wanted to evaluate the commercial potential of an in-licensing opportunity. This was for an infectious disease indication with no approved therapies available at the time.

A high level of unmet need presented a great commercial opportunity.

...But a lack of analogues made it difficult to identify an optimal price

The pharma company needed an accurate price evaluation to feed into the commercial decision and aid their negotiation strategy.

Often, to evaluate the price potential of in-licensing opportunities, analogues are used. However, with no available treatments on the market and very short timelines, quantifying the price potential of the asset would be difficult!

Interviews with payers were a potential solution, however this came with its own challenges…

Download the full Case Study by filling in the form:

By clicking on the “Submit Request” button you are providing consent for us to store your data and contact you. You may withdraw your consent at any time by instructing us at .

View our Privacy Policy for more information.

Please note that Inpharmation literature and case study materials constitute Inpharmation intellectual property and are intended for the pharmaceutical industry. Inpharmation is under no obligation to distribute these materials to non-pharmaceutical industry employees or competitors.

Scroll Top